Last updated: February 14, 2026
Overview
NDC 62175-0890 is marketed as Lagevrio (molnupiravir), an oral antiviral drug developed primarily for COVID-19 treatment. It received Emergency Use Authorization (EUA) from the FDA in December 2021, with full approval pending. The drug's market presence, competitive landscape, patent status, manufacturing capacity, pricing, and projected revenue form the core of this analysis.
Market Landscape
Molnupiravir entered the COVID-19 antiviral landscape dominated by Paxlovid (Pfizer) and Lagevrio (Merck). Its market share has depended on several factors:
- Regulatory approvals: EUA granted in the US (Dec 2021), expanded authorizations in multiple countries.
- Competitors: Paxlovid retains a competitive advantage due to earlier availability and higher clinical efficacy.
- Treatment guidelines: Incorporation into national COVID-19 treatment protocols influences prescribing patterns.
- Supply and manufacturing: Merck scaled manufacturing capacity rapidly, with estimates of producing over 10 million courses in 2022.
Market size assessment
The global COVID-19 antiviral market is evolving:
| Metric |
Value |
Notes |
| Estimated global COVID-19 cases (2022) |
650 million |
According to WHO[1]. |
| Target population (high-risk, mild cases) |
10-15% of cases |
Approximate focus group per clinical trial population[2]. |
| Total potential market (globally) |
65-97.5 million courses |
Assuming ~15% of cases are eligible and accessible. |
| Current global antiviral course distribution |
~20 million courses (2022) |
Based on manufacturing output and procurement reports[3]. |
Pricing structure
- Initial US Price: ~$700 per treatment course (per Merck's announced pricing).
- International prices: Range from $200 to $400 per course, depending on country negotiations.
- Government Contracts: Favorable pricing contracts primarily with the US government, which acquired large stockpiles at discounted rates (~$700).
Revenue Projections
Given current market conditions, the following projections apply:
| Year |
Estimated Sales |
Notes |
| 2022 |
$1.4 billion |
Based on 2 million courses sold at $700 each, accounting for some stockpiling[4]. |
| 2023 |
$2.5 billion |
Increased adoption, expanded indications, and ongoing purchasing agreements. |
| 2024 |
$3.0 billion |
Potential growth driven by new variants, expanded approvals, and increased manufacturing capacity. |
| 2025+ |
Stabilization or decline |
Future sales depend on competition and pandemic trends. |
Pricing Trends and Factors Influencing Price
- Patent Status: Merck holds active composition and method patents in the US until at least 2030[5], preventing generic competition.
- Patent Expiry and Generics: No generic competition is expected before 2030, maintaining pricing power.
- Regulatory Outcomes: Full approval could entrench pricing or trigger negotiations for lower prices internationally.
- Supply chain considerations: Manufacturing bottlenecks may temporarily affect supply and pricing.
- Competitor Dynamics: Paxlovid remains the dominant antiviral. Its high efficacy (~89% reduction in hospitalization) influences Lagevrio’s market share and potential price discounts.
Regulatory and Legal Factors
- Patent protection: Key patents extend into the 2030s, securing market exclusivity.
- Compulsory licensing: Countries like India pursue licensing and local manufacturing, potentially lowering prices.
- Pricing policies: US and European agencies are scrutinizing high COVID-19 drug prices, which may influence future pricing negotiations.
Key Takeaways
- Lagevrio commands a premium price of ~$700 per course in the US.
- Market size remains driven by the high-risk, mild COVID-19 case population, estimated at up to 97.5 million courses globally.
- Sales are projected to reach approximately $2.5 billion in 2023, with potential for growth subject to approval expansion and manufacturing scale-up.
- Patent protection until at least 2030 maintains pricing power; competition and policy changes could alter this landscape.
- International prices are notably lower, influenced by negotiated agreements and licensing agreements.
FAQs
-
What limits the market penetration of Lagevrio?
Its lower efficacy compared to Paxlovid and delayed FDA full approval limit clinical adoption.
-
When is generic production expected?
No generics are expected before 2030 due to patent protection.
-
How does patent protection influence pricing?
It maintains monopoly pricing and basis for premium sales, especially in the US.
-
What impact could international licensing have?
It could lower prices and expand access in LMICs but may reduce margins in core markets.
-
Are there new indications that could boost sales?
Pending research on prophylactic and broader antiviral use could expand the market.
Sources
- WHO COVID-19 Dashboard, 2022.
- Merck press releases, 2021-2022.
- International procurement reports, 2022.
- Industry analyst reports, 2022.
- U.S. Patent and Trademark Office records, 2022.
